Vitarka Therapeutics
Curing the untreated
Sandwich, United Kingdom · Founded 2021 · $1.6M raised
- Headquarters
- Sandwich
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- vitarka.co.uk
- Total Funding
- $1.6M
- Last Round
- SeedApr 2023
About
Founded in 2021 by Dr. Vineeta Tripathi, Vitarka Therapeutics Ltd is based in Sandwich, Kent, UK at the Discovery Park innovation campus. The company is addressing the endosomal entrapment problem — a key barrier to intracellular drug delivery — through its proprietary EndoPore platform, which uses pore-forming proteins to deliver small interfering RNA (siRNA) drugs directly to intracellular targets in tumor cells. Unlike antibody-drug conjugates (ADCs), EndoPore's dual mechanism of tumor selectivity limits toxicity to normal tissue and avoids linker instability issues. Vitarka raised £1.27 million (~$1.58M USD) in 2023 from SOSV's IndieBio accelerator and has presented at RNA therapeutics and oncology conferences. The company targets late-stage cancers where existing delivery technologies fail.
Summary
Vitarka Therapeutics is a Biotech company based in Sandwich, United Kingdom, founded in 2021. It has raised $1.6M in total, most recently a Seed round in Apr 2023.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...